Literature DB >> 954669

The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas.

R A Pederson, J C Brown.   

Abstract

Gastric inhibitory polypeptide (GIP) produced a dose-related increase in immunoreactive insulin (IRI) from the perfused isolated rat pancreas. The doses employed were within physiological limits. This effect was glucose-concentration-dependent in that there existed a threshold concentration of glucose above which GIP exerted the insulinotropic action, and that, at a fixed concentration of GIP, increased glucose concentrations stimulated IRI release in more than an additive manner. A biologically active fragment of the GIP molecule was isolated and purified. All criteria have been satisfied that GIP is an insulinotropic hormone.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 954669     DOI： 10.1210/endo-99-3-780

Source DB:  PubMed          Journal:  Endocrinology        ISSN： 0013-7227            Impact factor:   4.736


  28 in total

1.  Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice.

Authors:  N Irwin; P L McClean; F P M O'Harte; V A Gault; P Harriott; P R Flatt
Journal:  Diabetologia       Date:  2007-05-08       Impact factor: 10.122

Review 2.  The incretin concept today.

Authors:  W Creutzfeldt
Journal:  Diabetologia       Date:  1979-02       Impact factor: 10.122

3.  Insulin-dependent inhibition of hepatic glycogenolysis by gastric inhibitory polypeptide (GIP) in perfused rat liver.

Authors:  H Hartmann; R Ebert; W Creutzfeldt
Journal:  Diabetologia       Date:  1986-02       Impact factor: 10.122

4.  Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.

Authors:  S Mojsov; G C Weir; J F Habener
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

5.  GIP and the metabolic response to carbohydrate and fat.

Authors:  W Creutzfeldt
Journal:  Diabetologia       Date:  1984-10       Impact factor: 10.122

6.  Gastric inhibitory polypeptide (GIP) and insulin in obesity: increased response to stimulation and defective feedback control of serum levels.

Authors:  W Creutzfeldt; R Ebert; B Willms; H Frerichs; J C Brown
Journal:  Diabetologia       Date:  1978-01-14       Impact factor: 10.122

7.  Adrenergic modulation of gastric inhibitory polypeptide secretion in man.

Authors:  M Salera; R Ebert; P Giacomoni; L Pironi; S Venturi; R Corinaldesi; M Miglioli; L Barbara
Journal:  Dig Dis Sci       Date:  1982-09       Impact factor: 3.199

8.  Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels.

Authors:  D K Andersen; D Elahi; J C Brown; J D Tobin; R Andres
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

9.  Discrepancies between the doses of cholecystokinin or caerulein-stimulating exocrine and endocrine responses in perfused isolated rat pancreas.

Authors:  M Otsuki; C Sakamoto; H Yuu; M Maeda; S Morita; A Ohki; N Kobayashi; K Terashi; K Okano; S Baba
Journal:  J Clin Invest       Date:  1979-03       Impact factor: 14.808

10.  Glucose-dependent insulinotropic peptide: structure of the precursor and tissue-specific expression in rat.

Authors:  C C Tseng; L A Jarboe; S B Landau; E K Williams; M M Wolfe
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.